Losartan Potassium & Hydrochlorothiazide Tablets, USP, 50 mg/12.5 mg, a) 30-count bottles (NDC# 3...
FDA Drug Recall #D-0835-2022 — Class II — April 15, 2022
Recall Summary
| Recall Number | D-0835-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 15, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Macleods Pharma Usa Inc |
| Location | Plainsboro, NJ |
| Product Type | Drugs |
| Quantity | N/A |
Product Description
Losartan Potassium & Hydrochlorothiazide Tablets, USP, 50 mg/12.5 mg, a) 30-count bottles (NDC# 33342-050-07), b) 90-count bottles (NDC # 33342-050-10) c) 1000-count bottles (NDC # 33342-050-44), Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536
Reason for Recall
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Distribution Pattern
Product was distributed nationwide.
Lot / Code Information
Lot # BLK2107B, exp. date 05/2023 BLK2101A, exp. date 01/2025 BLK2102A, exp. date 02/2025 BLK2103B, exp. date 02/2023 BLK2103C, exp. date 02/2023 BLK2104A, exp. date 05/2023
Other Recalls from Macleods Pharma Usa Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1174-2022 | Class II | Eszopiclone Tablets, USP 1 mg, packaged in 30-... | Jun 16, 2022 |
| D-1164-2022 | Class II | Losartan potassium & Hydrochlorothiazide Tablet... | Jun 10, 2022 |
| D-0833-2022 | Class II | Losartan Potassium Tablets, USP, 50 mg, a) 30-c... | Apr 15, 2022 |
| D-0832-2022 | Class II | Losartan Potassium Tablets, USP, 25 mg, a) 90-c... | Apr 15, 2022 |
| D-0834-2022 | Class II | Losartan Potassium Tablets, USP, 100 mg, a) 30-... | Apr 15, 2022 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.